Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
XYLAZINEHYDROCHLORIDE
CP-Pharma Handelsgesellschaft mbH
QN05CM92
XYLAZINEHYDROCHLORIDE
Oplossing voor injectie
XYLAZINEHYDROCHLORIDE 116,55 mg/ml,
Intraveneus gebruik, Intramusculair gebruik
Uitsluitend door dierenartsen te gebruiken
Honden; Katten; Paarden; Runderen
Xylazine
Wachttermijn: Paarden Melk 0 uur; Paarden Vlees 1 dagen; Runderen Melk 0 uur; Runderen Vlees 1 dagen
NL/V/0158/002
2012-04-10
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Xylasol 100 mg/ml, solution for injection for cattle and horses (ES, HU, NL) Xylavet 100 mg/ml, solution for injection for cattle and horses (DE) 2. QUALITATIVE AND QUANTITIVE COMPOSITION Per ml: ACTIVE SUBSTANCE: Xylazine (as hydrochloride) 100.0 mg (equivalent to 116.55 mg xylazine hydrochloride) EXCIPIENTS: Methyl parahydroxybenzoate (E218) 1.0 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (≥ 200 kg) and horses. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Sedation. Premedication in combination with an anaesthetic. 4.3 CONTRAINDICATIONS • Do not use in animals with gastrointestinal obstruction as the muscle relaxant properties of the drug appear to accentuate the effects of the obstruction and because of possible vomiting. • Do not use in animals with severe renal or hepatic impairment, respiratory dysfunction, cardiac abnormalities, hypotension and/or shock. • Do not use in diabetic animals. • Do not use in animals with a history of seizures. • Do not use in cattle weighing less than 200 kg bodyweight. Do not use in foals younger than 2 weeks. • Do not use during the last stage of pregnancy (danger of premature birth), except at parturition (see section 4.7). 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Horses: • Xylazine inhibits the normal intestinal motility. Therefore, it should only be used in horses with colic, that are not responsive to analgesics. The use of xylazine should be avoided in horses with caecal malfunction. • After treatment of horses with xylazine, the animals are reluctant to walk, so whenever possible the drug should be administered in the place where the treatment/investigation is going to take place. • Caution should be taken in the administration of the product to horses susceptible to laminitis. • Horses with airway disease or malfunction may d Lees het volledige document